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We sought to measure changes in CTCL incidence trends and 5-year survival rates.
Methods
Incidence data were derived from the 9 original registries of the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute for incidence and survival data trends from 1973 to 2009, which covers 9.5% of the US population.
3 Data for 1992 to 2009 were derived from 4 additional registries (Los Angeles, California; San Jose, California; Alaska; and rural Georgia) from SEER 13. 4 Institutional review board approval was not required for use of this public database. Cases of CTCL were defined according to the International Classification of Diseases for Oncology (ICD-O). Primary site of skin was coded 44.0 through 44.9. The CTCL diagnoses were coded as the following: MF (9700), Sézary syndrome (9701), mature T-cell lymphoma not otherwise specified (NOS) (9702), angioimmunoblastic T-cell lymphoma (9705), subcutaneous panniculitis-like T-cell lymphoma (9708), CTCL NOS (9709), CD30 + T-cell lymphoproliferative disorders of the skin (9714, 9718), extranodal natural killer (NK)/T-cell lymphoma, nasal type (9719), and adult T-cell leukemia/lymphoma (9827). Subgroups of race, sex, registry, and age were classified by the SEER program. Demographic information was based on data from the US Census Bureau: State and County QuickFacts 2007-2011. 5 IMPORTANCE Cutaneous T-cell lymphoma (CTCL) incidence and survival have been increasing steadily for over 25 years.
OBJECTIVE We sought to measure changes in CTCL incidence trends and survival rates.
DESIGN, SETTING, AND PARTICIPANTS Population-based study. The CTCL incidence and survival data were obtained from the 9 original registries CONCLUSIONS AND RELEVANCE The incidence of CTCL is no longer increasing. Causes for this trend change may include real incidence stabilization, stabilization of physician detection, or artifact.
Statistical Analysis
Data were analyzed using Stata SE, version 8 (StataCorp), and SEER*Stat, version 7.0.5 (National Cancer Institute) statistical software. Incidence rates were age-adjusted to the 2000 US standard population and are reported per million persons. Linear regression was used to evaluate incidence trends. Trends for overall CTCL and subgroups of CTCL (age, sex, race, and registry) were analyzed using the Joinpoint Regression Program 4.0.1 (National Cancer Institute). The Joinpoint Regression Program uses permutation testing among other statistical methods to optimize standard errors and determine the number of times a trend changes. Owing to the relative rarity of CTCL, a log-linear model was applied to our data to enable report of an annual percent change instead of a fixed annual rate of change. A joinpoint year is defined as the year in which a statistically significant trend change was found. In cases when zero values were found for the dependent variable, which prevents the use of Joinpoint software to analyze trends, sensitivity analysis was performed.
Five-year relative survival rates were calculated using the actuarial method in SEER*Stat 7.0.5; cases with a missing or unknown cause of death were excluded from analysis. The period of survival was defined as the date of diagnosis to the date of last contact, death, or December 31, 2009.
Results

Overall CTCL Incidence
The total number of cases of CTCL from 1973 to 2009 was 6230. Per million persons, the annual age-adjusted incidence rate during this period was 7.5. Overall incidences and incidences by subgroups per 5-year period between 1973 and 2009 are reported in Table 1 .
We observed a statistically significant stabilization of overall CTCL incidence ( Figure) . This change in incidence trend occurred in 1998 (95% CI,1994-2002) ( Table 2) . Prior to 1998, overall CTCL incidence increased by 5.7% per year (95% CI, 4.9%-6.5%). Between 1998 and 2009, the annual percent change (APC) for CTCL was 0.1% (95% CI, −1.4% to 1.5%).
CTCL Subgroup Analysis
Subgroups of age, sex, race, and registry, when found to have a pattern of incidence stabilization, showed a steady increase in incidence until a joinpoint year, followed by an incidence rate that was not significantly different from 0. The joinpoint years, or years in which a statistically significant change in trend was found, vary as listed in Table 2 . Abbreviations: CTCL, cutaneous T-cell lymphoma; IRR, incidence rate ratio; SEER, Surveillance, Epidemiology, and End Results Registries.
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In our age group analysis, we found a consistent pattern of CTCL incidence stabilization for ages 0 to 54, 55 to 69, and 70 to 84 years. The joinpoint years and annual percent change from 1973 to the joinpoint year are listed in Table 2 . No pattern of incidence stabilization was found in individuals 85 years or older. The CTCL incidence increased with age, a trend consistent with the literature. The highest CTCL incidence was found was in those aged 70 to 84 years (Table 1) .
Sex analysis showed a stabilization of CTCL incidence for both men and women. Annual percent change and joinpoint years are listed in Table 2 . The male to female incidence rate ratio (IRR) has been approximately 2:1 in the past. We observed a statistically significant downward trend in the male to female IRR from 2. Race analysis showed a stabilization of CTCL incidence for both blacks and whites; annual percent changes and joinpoint years are listed in Table 2 . Blacks have consistently had a higher incidence of CTCL, but the ratio has changed erratically with no consistent trend. The black to white IRR for the most recent period of 2005 to 2009 was 1.28.
The diagnosis of MF alone also showed a stabilization of incidence, with a joinpoint year of 1984 (95% CI, 1981-1986). Prior to 1984, the APC was 7.8% (95% CI, 4.9%-10.7%), and after 1984, it was 0.5% (95% CI, 0.0%-1.0%). Trend changes in other CTCL diagnoses were not analyzed owing to a small number of cases. Age-adjusted incidence rates for MF are reported in Table 1 .
Sensitivity analysis of all combinations of the 9 original registries after exclusion of any 2 showed a consistent stabilization of incidence. The highest CTCL incidence in both the earliest period and the most recent period was in San Francisco ( Table 1 ). The incidence of CTCL between different registries within California varied significantly. Specifically, San Francisco had a much higher age-adjusted incidence rate in both 1992 and in 2009 than di San Jose. In 1992, the CTCL incidence in San Francisco was 13.4 per million persons (95% CI, 9.9-17. 
Survival Analysis
In the earliest period of 1973 to 1980, overall CTCL survival was 71.5% (95% CI, 66.2%-78.8%). In the most recent period evaluated (1997-2005), overall CTCL survival was 78.3% (95% CI, 76.3%-81.3%). We found a statistically significant increase in 5-year survival rates from 1973 through 2004 (P = .01). However, we did not find any further statistically significant increase in survival after that period. The last year for which 5-year survival data were available was 2005.
Associated Factors
We evaluated correlations between CTCL incidence in whites and demographic characteristics of the 9 original registries between 1973 and 2009 and the 4 additional registries between 1992 and 2009. Consistent with prior report, CTCL incidence was correlated with median household income (r = 0.7, P = .01) 
Discussion
We used comprehensive data from the original registries of the SEER program to evaluate temporal incidence trends in CTCL. A continuous increase in CTCL incidence has been documented since the early 1970s. 1, 6 We report a significant change in this trend. In recent years, incidence of overall CTCL has stabilized, a finding that is consistent across subgroups of race, sex, age, diagnosis, and location. This trend change has been previously reported. Bradford et al 2 studied the SEER registries and noticed an apparent decrease in CTCL incidence from 2001 to 2005, a trend inconsistent with previous steady increases in incidence. Though the finding was not studied in detail or extensively over time, the authors suggested delayed identification and reporting as possible causes for the trend change. 2 We propose that the cause of this trend change is multifactorial. Substantial improvements in medical care have been reported over the past few decades. 7 Given the correlation between physician density and increased CTCL incidence, a proposed reason for a persistent increase in incidence in the past has been increased efficiency of physician detection. 1 We suggest that improvements in physician detection may have stabilized as they approach a natural maximum, resulting in apparent incidence stabilization. A true increase in the number of cases has also been proposed in increasing CTCL incidence. Both improved physician detection and an increase in the true number of cases have been shown to be the primary causes of increased incidence in the cases of other malignant conditions such as thyroid cancer. 8, 9 Similarly, a true increase in the number of CTCL cases may indeed have contributed to a past increase in CTCL incidence. A corresponding true stabilization in the number of cases may play a role in our findings of CTCL incidence stabilization. If a true stabilization in CTCL incidence is present, the cause for it remains unknown. We cannot exclude that our findings may be due to artifact. One major limitation to the study of CTCL over time is change in ICD-O coding. The diagnoses that fall under CTCL as a group have been redistributed several times in the past few decades, with the most recent change in ICD-O coding applied to CTCL cases starting in 2001. 10 Coding changes have resulted primarily in shifts of distribution of CTCLs among subcategories instead of major insertions or deletions. However, the joinpoint year for overall CTCL incidence stabilization as well as for each of the subgroups analyzed tended to be near 2001 (Table 2) . It is thus possible that ICD-O coding changes may have contributed to our findings. Apparent stabilization of MF incidence has been reported in the past 11 ; redistribution in ICD-O coding has been considered the reason for that finding. 13 While we do not have specific evidence on delayed reporting since that time, this finding makes it unlikely that delayed reporting played a primary role in our findings.
Incidence of CTCL in men has been higher than that in women since at least 1973, with a male to female ratio of roughly 2.
2, 6 The ratio decrease we reported appears to be due to a faster rate of increase in female CTCL incidence, which has quadrupled between 1973 and 2009, compared with male CTCL incidence, which tripled during that period. Incidence varied greatly by geographic location. Of note, we reported that 2 registries in California, San Jose and San Francisco, had drastically different age-adjusted incidences both in the past and in the most recent period, though they are located within 50 miles of each other. Access to and utilization of health care may play a role in these differences. Incidence has been correlated with high physician density. We confirmed that other indices of socioeconomic status such as median family income and median home value are correlated with CTCL incidence. 1 Further analysis of hospitalization rates or insurance rates in those diagnosed with CTCL may be informative in evaluation of confounding by access to health care. We did not confirm previously reported correlation of incidence with population density 11 or with percentage of population with a bachelor's degree or higher education level, 1 although we did find a trend toward higher education level. It has been previously suggested that the high incidence of CTCL in San Francisco follows an incidence trend observed in other HIV-related cancers such as non-Hodgkin lymphoma and Kaposi sarcoma. 1, 14 Atypical cutaneous lymphoproliferative disorder, a term used to describe a lymphoproliferative disorder that closely mimics MF clinically and histopathologically, has been reported in association with human immunodeficiency virus (HIV). 15, 16 However, MF itself is not a known complication of HIV. In addition, unlike the HIVrelated cancers, a previous case-control study failed to find an increased risk for CTCL among never-married men. 1, 17, 18 Thus, while an association has been suggested, it is unlikely that HIV plays a role in the geographical variation in incidence we report. The heterogeneity in CTCL incidence rates among the registries provides an avenue for further research. We presented associations that suggest a role for socioeconomic factors in geographical variation in CTCL incidence, but further investigation is required to identify specific causes for these differences. A substantial and steady increase in survival from CTCL has been reported from 1973 to 1992, but advanced age and black race were associated with poorer survival. 19 We confirmed a continued increase in survival through 2004 but not after that. Analysis of more recent data is necessary to deter-
